Envisioning 2.0

From In the Pipeline:

“Hepatitis C has been one of the big targets for many years now. Various development programs have come and gone, but no one has been able to really nail this one. Vertex is now in the middle of trying to, and as Adam Feuerstein points out, they’re really betting a large part of the company on the attempt. Over the next few months, results should start coming out for their PROVE trials of telaprevir (VX-950), and for Vertex’s sake, the drug had better work. A herd of competitors, probably led by Schering-Plough, is ready to take over should anything slip.”

For my thoughts on this drug, please see the following posts:

-VX-950: Hep-C Treatment Moving Right Along
-Don’t Believe The Hype — Yet

This entry was posted on February 7, 2007 at 4:28 pm and is filed under The Pharmaceutical Industry. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.